• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biotech Acquisition Company

    1/27/23 1:18:05 PM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOT alert in real time by email
    SC 13G 1 tm234623d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. )

     

    Biotech Acquisition Company
    (Name of Issuer)
     
    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G1125A108
    (CUSIP Number)
     
    January 25, 2023
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Radcliffe Capital Management, L.P.

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    405,900

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    405,900

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    405,900

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.39%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    RGC Management Company, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    405,900

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    405,900

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    405,900

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.39%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, OO

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Steven B. Katznelson

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canada, United States of America and the United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    405,900

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    405,900

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    405,900

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.39%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Christopher Hinkel

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    405,900

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    405,900

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    405,900

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.39%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Radcliffe SPAC Master Fund, L.P.

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    405,900

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    405,900

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    405,900

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.39%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

           

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    Radcliffe SPAC GP, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     ¨

    (b)     x

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    405,900

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    405,900

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    405,900

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.39%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, OO

           

     

     

     

    Item 1(a).

    Name of Issuer:

    Biotech Acquisition Company

       
    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    545 West 25th Street, 20th Floor

    New York, NY 10001

       
    Item 2(a). Name of Person Filing:
     

    Radcliffe Capital Management, L.P.

    RGC Management Company, LLC

    Steven B. Katznelson

    Christopher Hinkel

    Radcliffe SPAC Master Fund, L.P.

    Radcliffe SPAC GP, LLC

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:
     

    50 Monument Road, Suite 300

    Bala Cynwyd, PA 19004

     

    Item 2(c). Citizenship:
     

    Radcliffe Capital Management, L.P. – Delaware, United States of America

    RGC Management Company, LLC – Delaware, United States of America

    Steven B. Katznelson – Canada, United States of America and the United Kingdom

    Christopher Hinkel – United States of America

    Radcliffe SPAC Master Fund, L.P. – Cayman Islands

    Radcliffe SPAC GP, LLC – Delaware, United States of America

     

    Item 2(d). Title of Class of Securities:
      Class A ordinary shares, par value $0.0001 per share
       
    Item 2(e). CUSIP Number:
     

    G1125A108

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)

    Amount beneficially owned:

     

    405,900 shares deemed beneficially owned by Radcliffe Capital Management, L.P.

    405,900 shares deemed beneficially owned by RGC Management Company, LLC

    405,900 shares deemed beneficially owned by Steven B. Katznelson

    405,900 shares deemed beneficially owned by Christopher Hinkel

    405,900 shares deemed beneficially owned by Radcliffe SPAC Master Fund, L.P.

    405,900 shares deemed beneficially owned by Radcliffe SPAC GP, LLC

     

      (b)

    Percent of class:

     

    5.39% shares deemed beneficially owned by Radcliffe Capital Management, L.P.

    5.39% shares deemed beneficially owned by RGC Management Company, LLC

    5.39% shares deemed beneficially owned by Steven B. Katznelson

    5.39% shares deemed beneficially owned by Christopher Hinkel

    5.39% shares deemed beneficially owned by Radcliffe SPAC Master Fund, L.P.

    5.39% shares deemed beneficially owned by Radcliffe SPAC GP, LLC

     

      (c) Number of shares as to which Radcliffe Capital Management, L.P. has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 405,900
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 405,900
        Number of shares as to which RGC Management Company, LLC has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 405,900
        (iii) Sole power to dispose or to direct the disposition of: 0

     

     

     

     

        (iv) Shared power to dispose or to direct the disposition of: 405,900
        Number of shares as to which Steven B. Katznelson has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 405,900
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 405,900
        Number of shares as to which Christopher Hinkel has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 405,900
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 405,900
        Number of shares as to which Radcliffe SPAC Master Fund, L.P. has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 405,900
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 405,900
        Number of shares as to which Radcliffe SPAC GP, LLC has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 405,900
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 405,900
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o Not applicable
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      With the exception of the securities reported in this Schedule 13G that are owned by the Radcliffe SPAC Master Fund, L.P., none of Radcliffe Capital Management, L.P.’s advisory clients individually own more than 5% of the Issuer’s outstanding common stock.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      See Exhibit B attached hereto.

     

     

     

     

    Item 8. Identification and Classification of Members of the Group:
      Not applicable
    Item 9. Notice of Dissolution of Group:
      Not applicable
    Item 10. Certifications:
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      January 27, 2023
      (Date)
     

     

    Radcliffe Capital Management, L.P.

    By RGC Management Company, LLC,

    its General Partner*

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    RGC Management Company, LLC*

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

       
    Steven B. Katznelson*

    /s/Loretta Best
    Signature

     

    Attorney-in Fact**

     

    Christopher Hinkel*

    /s/Loretta Best
    Signature

     

    Attorney-in Fact**

     

    Radcliffe SPAC Master Fund, L.P.

    By Radcliffe SPAC GP, LLC,

    its General Partner*

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    Radcliffe SPAC GP, LLC*

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    *The Reporting Person specifically disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

     

     

     

     

    **Loretta Best is signing on behalf of Steven B. Katznelson and Christopher Hinkel as attorney-in-fact pursuant to powers of attorney filed with the Securities and Exchange Commission as Exhibits 99.1 and 99.2, respectively, to a filing by Radcliffe Capital Management, L.P. on Schedule 13G on August 30, 2021.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (see 18 U.S.C. 1001).

     

     

     

     

    Exhibit A

     

    Agreement

     

    The undersigned agree that this Schedule 13G dated January 27, 2023 to the Class A ordinary shares, par value $0.0001 per share of Biotech Acquisition Company shall be filed on behalf of the undersigned.

     

      January 27, 2023
      (Date)
     

     

    Radcliffe Capital Management, L.P.

    By RGC Management Company, LLC,

    Its General Partner

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    RGC Management Company, LLC

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

       
    Steven B. Katznelson

    /s/Loretta Best
    Signature

     

    Attorney-in Fact**

     

    Christopher Hinkel

    /s/Loretta Best
    Signature

     

    Attorney-in Fact**

     

    Radcliffe SPAC Master Fund, L.P.

    By Radcliffe SPAC GP, LLC,

    its General Partner

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    Radcliffe SPAC GP, LLC

    /s/Loretta Best
    Signature

     

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    **Loretta Best is signing on behalf of Steven B. Katznelson and Christopher Hinkel as attorney-in-fact pursuant to powers of attorney filed with the Securities and Exchange Commission as Exhibits 99.1 and 99.2, respectively, to a filing by Radcliffe Capital Management, L.P. on Schedule 13G on August 30, 2021.

     

     

     

     

    Exhibit B

     

    Radcliffe Capital Management, L.P. is the relevant entity for which RGC Management Company, LLC, Steven B. Katznelson and Christopher Hinkel may be considered control persons. Radcliffe SPAC Master Fund, L.P. is the relevant entity for which Radcliffe SPAC GP, LLC, Steven B. Katznelson and Christopher Hinkel may be considered control persons.

     

     

     

     

     

     

    Get the next $BIOT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

      SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

      2/14/24 9:12:34 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

      SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

      2/14/23 10:50:25 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biotech Acquisition Company

      SC 13G - Biotech Acquisition Co (0001825413) (Subject)

      2/14/23 10:35:55 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Biotech Acquisition Company

      15-12G - Biotech Acquisition Co (0001825413) (Filer)

      2/14/23 4:40:30 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Biotech Acquisition Company

      25-NSE - Biotech Acquisition Co (0001825413) (Subject)

      2/2/23 4:55:30 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biotech Acquisition Company filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Biotech Acquisition Co (0001825413) (Filer)

      2/1/23 8:00:32 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biotech Acquisition Company Announces Liquidation

      New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem

      2/1/23 7:50:00 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding an

      1/4/23 5:51:00 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology Conference

      Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the "Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need" panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET), during the 2022 BTIG Biotechnology Conference, August 8 – 9, in New York City. Blade's lead investigational medicine is cudetaxestat, a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial i

      8/1/22 8:00:00 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development

      Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t

      11/18/21 8:00:00 AM ET
      $AMGN
      $BIOT
      $FGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations